Streetwise Biotech / Pharmaceuticals Articles



Andrea Bartzen

Convergence Will Drive the Ultimate Disruption of Life Sciences
Source: Andrea Bartzen for Streetwise Reports  (3/28/18)
Andrea Bartzen, a strategic commercial and communication consultant, describes the disruptive technologies positioned to radically alter the business of life sciences as discussed at a recent BIO CEO Summit Investor Night.
More >


Biotech Advances Treatments for Liver Disease, Pain, Mental Illness
Source: Streetwise Reports  (3/22/18)
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018.
More >


Two Biotechs Earn Analyst's Top Pick Ranking
Source: Streetwise Reports  (3/19/18)
Echelon Wealth Partners analyst Doug Loe sees blue sky potential for one company's newly approved HIV compound, while the vaccine platform of a second company earned it Top Pick status as well.
More >


Price Target on Biotech Is a 700% Potential Increase
Source: Streetwise Reports  (3/19/18)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., explained Phase 2 data recently released by this company, which documented improvements in patients with inflammatory bowel disease. More >


Biotech's Encouraging Phase 2 Gut Microbiome Data 'Bodes Well' for Phase 3
Source: Streetwise Reports  (3/14/18)
H.C. Wainwright & Co. analyst Ram Selvaraju reported the latest study findings involving this biotherapeutic firm's lead asset. More >


Coverage Initiated on Biotech; Analyst Says, 'Time to Buy'
Source: Streetwise Reports  (3/14/18)
Sarah Weber, an analyst with Piper Jaffray & Co., made the case for investing in this biotherapeutic development firm. More >


Coverage Initiated on Biotech with Interference RNA Platform; Target Price Shows 600% Upside
Source: Streetwise Reports  (3/7/18)
John Vandermosten, an analyst with Zacks Small-Cap Research, analyzed this therapeutics development firm as an investment. More >


Biotech Launches Trial Dosing Against Backdrop of Strong Balance Sheet
Source: Streetwise Reports  (3/7/18)
Four analysts provided updates regarding the status of this firm's financials and one of its clinical programs. More >


Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'
Source: Streetwise Reports  (2/23/18)
Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential.
More >


Steve Palmer

Fund Manager Names Three Small-Caps with Strong Growth Profiles
Source: Streetwise Reports  (2/22/18)
The annual AlphaNorth Capital Conference features small-cap non-resource companies with high growth prospects. AlphaNorth's founder and chief investment officer, Steve Palmer, profiles several companies that he believes have bright prospects.
More >


Analyst's $70 Target Price on Regenerative Medicine Biotech More than a Triple
Source: Streetwise Reports  (2/20/18)
One analyst believes an innovative biotech company that has developed groundbreaking technology to change the way doctors perform body tissue engineering, like skin grafting on burn victims, has the potential to "revolutionize the field of regenerative medicine." More >


Biotech with Tenbagger Potential Signs Deal with Chinese Firm
Source: Streetwise Reports  (2/14/18)
Joseph Pantginis, an analyst with H. C. Wainwright & Co., detailed prospects for this biopharmaceutical corporation's new partnership with an Asian biotech and other near-term plans.
More >


Ron Struthers

The S-Curve Reveals It Is Early Days in the Marijuana Growth Cycle
Source: Ron Struthers for Streetwise Reports  (2/12/18)
Ron Struthers of Struthers Resource Stock Report discusses recent trends in cannabis investing and profiles a handful of cannabis companies. More >


Oncology Biotech with Precision Medicine Focus Added to Analyst's 2018 Top-Pick List
Source: Streetwise Reports  (2/7/18)
A small-cap biotech focused on developing customized treatments for cancer patients has earned inclusion on the NASDAQ Biotechnology Index, as well as caught the eye of analyst Michael King of JMP Securities. More >


Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'
Source: Streetwise Reports  (2/7/18)
Maxim Group analyst Jason McCarthy explained why investors should focus on this emerging technology and one developer that is well-positioned to capture value in the space. More >


Coverage Initiated on Developer of Potential Breast Cancer Therapy Competitor
Source: Streetwise Reports  (1/31/18)
Jason Kolbert, an analyst with Maxim Group, explained the drivers behind adding this drug and drug delivery developer to his coverage universe. More >


Preliminary Phase 2 Clinical Data Provides 'First Spark to Game-Changing Thesis'
Source: Streetwise Reports  (1/31/18)
H.C. Wainwright & Co. reported on the significance of preliminary data for treatments for head and neck cancer, as well as for cervical cancer. More >


Pancreatic Cancer Trial Data Will Be Released Soon
Source: Streetwise Reports  (1/24/18)
A biotech company that has begun clinical testing of human antibodies to treat cancers is in discussion with potential partners. More >


Coverage Resumed on Developer of 'Drug Candidate with Blockbuster Potential'
Source: Streetwise Reports  (1/24/18)
André Uddin, an analyst with Mackie Research Capital Corp., shared his thesis for investing in this biotech.
More >


Regenerative Medicine Company's China Deal is 'Dramatically Transformational'
Source: Streetwise Reports  (1/18/18)
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance in Asia. More >


Several Milestones on Horizon for 'Top Pick' Immunotherapy Firm
Source: Streetwise Reports  (1/17/18)
Douglas Loe, an analyst with Echelon Partners, outlined the reasons this biotech deserves Top Pick status. More >


Test for Personalized Approach to Hodgkin's Lymphoma Treatment Entering Final Stages Before Commercialization
Source: Streetwise Reports  (1/16/18)
One analyst believes 2018 could mark a 'dramatic turnaround' for this biotech company, which is at the forefront of using three-dimensional telomere analysis to personalize medical treatment. More >


Biotech Offers 'Best-in-Class Potential to Treat Alzheimer's'
Source: Streetwise Reports  (1/10/18)
André Uddin, an analyst with Mackie Research Capital Corp., discussed the implications of the latest announcement about this firm's most advanced Alzheimer's drug. More >


John McCamant

Biotech with Non-Statin Cholesterol Lowering Drug Poised for Significant Catalysts in 2018
Source: John McCamant for Streetwise Reports  (1/10/18)
As 2018 begins, John McCamant, editor of Medical Technology Stock Letter, reviews several 2017 top performers, discusses the turnaround at the FDA, and profiles one company with an innovative non-statin LDL cholesterol in the pipeline. More >


Michael G. King, Jr.

2018 Biotech Watchlist: 'No One Space Is Going to Dominate'
Source: Streetwise Reports  (1/10/18)
Michael King of JMP Securities provides a comprehensive round-up of companies he has selected for the 2018 Biotech Watchlist—companies in immuno-oncology, gene editing, and other indications that he believes offer promising opportunities for patients and investors.
More >


Showing Results: 26 to 50 of 748 Prev Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts